• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Bio-Rad to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

    4/15/25 4:15:00 PM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $BIO alert in real time by email

    Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2025 on Thursday, May 1, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2:30 PM Pacific Time (5:30 PM Eastern Time) that day.

    To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live webcast of the conference call will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available for up to a year.

    About Bio-Rad

    Bio-Rad Laboratories, Inc. (NYSE:BIO) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,700 employees and $2.6 billion in revenues in 2024. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250415727519/en/

    Investor Contact:

    Edward Chung, Investor Relations

    510-741-6104

    [email protected]

    Media Contact:

    Anna Gralinska, Corporate Communications

    510-741-6643

    [email protected]

    Get the next $BIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BIO

    DatePrice TargetRatingAnalyst
    10/1/2024$350.00 → $400.00Neutral → Buy
    Citigroup
    8/28/2024$340.00Equal Weight
    Wells Fargo
    6/3/2024$315.00Hold
    Jefferies
    4/3/2024$400.00 → $365.00Buy → Neutral
    Citigroup
    12/7/2023$395.00Buy
    UBS
    6/16/2023$550.00Overweight
    Wells Fargo
    12/7/2022$565.00Outperform
    RBC Capital Mkts
    8/25/2022$715.00Outperform
    Credit Suisse
    More analyst ratings